$DVA
DAVITA INC.

2021 Q2 Form 10-Q Financial Statement

#000092706621000136 Filed on August 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $2.917B $2.880B
YoY Change 1.27% 1.31%
Cost Of Revenue $1.965B $1.985B
YoY Change -0.97% 1.37%
Gross Profit $951.2M $895.4M
YoY Change 6.24% 1.18%
Gross Profit Margin 32.62% 31.09%
Selling, General & Admin $298.1M $316.2M
YoY Change -5.73% 14.86%
% of Gross Profit 31.34% 35.31%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $169.7M $157.4M
YoY Change 7.81% 3.35%
% of Gross Profit 17.84% 17.58%
Operating Expenses $467.8M $473.5M
YoY Change -1.21% 10.76%
Operating Profit $490.5M $409.9M
YoY Change 19.65% -11.25%
Interest Expense -$66.30M -$77.10M
YoY Change -14.01% -39.39%
% of Operating Profit -13.52% -18.81%
Other Income/Expense, Net $15.19M $9.545M
YoY Change 59.12% 69.15%
Pretax Income $432.3M $338.1M
YoY Change 27.88% 4.44%
Income Tax $81.31M $83.21M
% Of Pretax Income 18.81% 24.61%
Net Earnings $293.8M $201.6M
YoY Change 45.74% -26.3%
Net Earnings / Revenue 10.07% 7.0%
Basic Earnings Per Share $2.76 $1.65
Diluted Earnings Per Share $2.64 $1.62
COMMON SHARES
Basic Shares Outstanding 106.4M shares 122.1M shares
Diluted Shares Outstanding 111.4M shares 124.1M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.114B $3.111B
YoY Change -64.19% -13.95%
Cash & Equivalents $1.044B $2.929B
Short-Term Investments $70.48M $182.5M
Other Short-Term Assets $232.2M $170.0M
YoY Change 36.59% 5.59%
Inventory $115.4M $97.90M
Prepaid Expenses
Receivables $1.947B $1.772B
Other Receivables $541.4M $614.6M
Total Short-Term Assets $3.979B $5.780B
YoY Change -31.16% -9.56%
LONG-TERM ASSETS
Property, Plant & Equipment $3.486B $3.418B
YoY Change 1.98% 0.37%
Goodwill $6.944B $6.791B
YoY Change 2.25% -1.09%
Intangibles $162.5M $113.4M
YoY Change 43.31% -5.97%
Long-Term Investments $279.2M $284.0M
YoY Change -1.7%
Other Assets $95.49M $92.91M
YoY Change 2.78% -4.65%
Total Long-Term Assets $13.83B $13.53B
YoY Change 2.27% -0.11%
TOTAL ASSETS
Total Short-Term Assets $3.979B $5.780B
Total Long-Term Assets $13.83B $13.53B
Total Assets $17.81B $19.31B
YoY Change -7.74% -3.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $376.3M $357.3M
YoY Change 5.31% -8.14%
Accrued Expenses $976.2M $1.047B
YoY Change -6.76% 4.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $184.4M $1.907B
YoY Change -90.33% -46.9%
Total Short-Term Liabilities $2.386B $4.275B
YoY Change -44.18% -25.1%
LONG-TERM LIABILITIES
Long-Term Debt $8.798B $7.895B
YoY Change 11.44% 46.8%
Other Long-Term Liabilities $157.7M $144.1M
YoY Change 9.41% 7.07%
Total Long-Term Liabilities $157.7M $144.1M
YoY Change 9.41% 7.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.386B $4.275B
Total Long-Term Liabilities $157.7M $144.1M
Total Liabilities $14.92B $15.73B
YoY Change -5.14% 8.46%
SHAREHOLDERS EQUITY
Retained Earnings $1.384B $1.873B
YoY Change -26.12% -41.58%
Common Stock $523.1M $719.2M
YoY Change -27.26% -27.29%
Preferred Stock
YoY Change
Treasury Stock (at cost) $563.2M $303.1M
YoY Change 85.8% 170.2%
Treasury Stock Shares
Shareholders Equity $1.278B $2.154B
YoY Change
Total Liabilities & Shareholders Equity $17.81B $19.31B
YoY Change -7.74% -3.14%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income $293.8M $201.6M
YoY Change 45.74% -26.3%
Depreciation, Depletion And Amortization $169.7M $157.4M
YoY Change 7.81% 3.35%
Cash From Operating Activities $679.7M $651.1M
YoY Change 4.4% -43.51%
INVESTING ACTIVITIES
Capital Expenditures -$149.5M -$136.8M
YoY Change 9.31% -178.15%
Acquisitions
YoY Change
Other Investing Activities -$9.761M -$107.8M
YoY Change -90.95% -102.85%
Cash From Investing Activities -$159.3M -$244.5M
YoY Change -34.85% -106.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -381.8M 1.143B
YoY Change -133.41% -169.86%
NET CHANGE
Cash From Operating Activities 679.7M 651.1M
Cash From Investing Activities -159.3M -244.5M
Cash From Financing Activities -381.8M 1.143B
Net Change In Cash 138.7M 1.549B
YoY Change -91.05% -50.35%
FREE CASH FLOW
Cash From Operating Activities $679.7M $651.1M
Capital Expenditures -$149.5M -$136.8M
Free Cash Flow $829.3M $787.9M
YoY Change 5.25% -19.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000927066
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q2 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
4760572000 USD
CY2020Q4 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
4480429000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
73215000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
70141000 USD
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
110644000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109933000 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105625000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109933000 shares
CY2021Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5019000 shares
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0 shares
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
dva Corporate Integrity Agreement Period
CorporateIntegrityAgreementPeriod
P5Y
CY2020Q4 dva Terminated Remaining Prior Share Repurchases Authorized Amount
TerminatedRemainingPriorShareRepurchasesAuthorizedAmount
329302000 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-14106
dei Entity Registrant Name
EntityRegistrantName
DAVITA INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0354549
dei Entity Address Address Line1
EntityAddressAddressLine1
2000 16th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80202
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
631-2100
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
DVA
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
104800000 shares
CY2021Q2 dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
2817957000 USD
CY2020Q2 dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
2758197000 USD
dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
5532544000 USD
dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
5471478000 USD
CY2021Q2 us-gaap Other Income
OtherIncome
98553000 USD
CY2020Q2 us-gaap Other Income
OtherIncome
121782000 USD
us-gaap Other Income
OtherIncome
203967000 USD
us-gaap Other Income
OtherIncome
249738000 USD
CY2021Q2 us-gaap Revenues
Revenues
2916510000 USD
CY2020Q2 us-gaap Revenues
Revenues
2879979000 USD
us-gaap Revenues
Revenues
5736511000 USD
us-gaap Revenues
Revenues
5721216000 USD
CY2021Q2 dva Patient Care Costs
PatientCareCosts
1965277000 USD
CY2020Q2 dva Patient Care Costs
PatientCareCosts
1984564000 USD
dva Patient Care Costs
PatientCareCosts
3903607000 USD
dva Patient Care Costs
PatientCareCosts
3960013000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
298091000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
316209000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
579517000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
579785000 USD
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
169689000 USD
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
157376000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
335390000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
312055000 USD
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
7023000 USD
CY2020Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
4342000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
15081000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
22185000 USD
CY2021Q2 us-gaap Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee
GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
0 USD
CY2020Q2 us-gaap Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee
GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
-16252000 USD
us-gaap Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee
GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
0 USD
us-gaap Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee
GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
-16252000 USD
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
2426034000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
2470059000 USD
us-gaap Costs And Expenses
CostsAndExpenses
4803433000 USD
us-gaap Costs And Expenses
CostsAndExpenses
4845920000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
490476000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
409920000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
933078000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
875296000 USD
CY2021Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
73324000 USD
CY2020Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
81381000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
140338000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
169984000 USD
CY2021Q2 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
CY2020Q2 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
2948000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15188000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5195000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
432340000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9545000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16356000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
338084000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
809096000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
707559000 USD
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
81309000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
83212000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
166520000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
174772000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
351031000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
254872000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
642576000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
532787000 USD
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 USD
CY2020Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
9980000 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
351031000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
254872000 USD
us-gaap Profit Loss
ProfitLoss
642576000 USD
us-gaap Profit Loss
ProfitLoss
542767000 USD
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
57211000 USD
CY2020Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
53270000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
111353000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
101572000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
293820000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
201602000 USD
us-gaap Net Income Loss
NetIncomeLoss
531223000 USD
us-gaap Net Income Loss
NetIncomeLoss
441195000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.76
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.65
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
4.94
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
3.49
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.76
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.57
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.64
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.62
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
4.72
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
3.44
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.64
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.52
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106364000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122074000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107606000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
123485000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111423000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
124068000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112555000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125479000 shares
CY2021Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
293820000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
201602000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
531223000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
431215000 USD
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2020Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
9980000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
293820000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
201602000 USD
us-gaap Net Income Loss
NetIncomeLoss
531223000 USD
us-gaap Net Income Loss
NetIncomeLoss
441195000 USD
CY2021Q2 us-gaap Profit Loss
ProfitLoss
351031000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-1824000 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
2823000 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-14842000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-1033000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-1623000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-2066000 USD
CY2020Q2 us-gaap Profit Loss
ProfitLoss
254872000 USD
us-gaap Profit Loss
ProfitLoss
642576000 USD
us-gaap Profit Loss
ProfitLoss
542767000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-2059000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-3246000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
57910000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
5619000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4634000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-76013000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
56884000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5418000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
255000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-87609000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
407915000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
260290000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
642831000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
455158000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
57211000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
53270000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
111353000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
101572000 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
350704000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
207020000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
531478000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
353586000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1043632000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
324958000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
111625000 USD
CY2021Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
541430000 USD
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
544376000 USD
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
162846000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
176832000 USD
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
36701000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20101000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1947466000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1824282000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
115369000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
69360000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
76387000 USD
CY2021Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
61782000 USD
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
70163000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
3978586000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
3148724000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3485600000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3521824000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2865320000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2863089000 USD
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
162484000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
166585000 USD
CY2021Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
245389000 USD
CY2020Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
257491000 USD
CY2021Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
33777000 USD
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
32193000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
95490000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
79501000 USD
CY2021Q2 us-gaap Goodwill
Goodwill
6943665000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
6919109000 USD
CY2021Q2 us-gaap Assets
Assets
17810311000 USD
CY2020Q4 us-gaap Assets
Assets
16988516000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
376264000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
434253000 USD
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
837284000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
810529000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
593859000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
685555000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
382342000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
369497000 USD
CY2021Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
184435000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
168541000 USD
CY2021Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
11856000 USD
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
7768000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2386040000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2476143000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2727323000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2738670000 USD
CY2021Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8798263000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
7917263000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
157687000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
150060000 USD
CY2021Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
851961000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
809600000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
14921274000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
14091736000 USD
CY2021Q2 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1426211000 USD
CY2020Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1330028000 USD
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
111000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
110000 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
523038000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
597073000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1383760000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
852537000 USD
CY2021Q2 us-gaap Treasury Stock Value
TreasuryStockValue
563230000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-65899000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-66154000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
1277780000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1383566000 USD
CY2021Q2 us-gaap Minority Interest
MinorityInterest
185046000 USD
CY2020Q4 us-gaap Minority Interest
MinorityInterest
183186000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1462826000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1566752000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17810311000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16988516000 USD
us-gaap Profit Loss
ProfitLoss
642576000 USD
us-gaap Profit Loss
ProfitLoss
542767000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
335390000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
312055000 USD
dva Debt Refinancing Charges
DebtRefinancingCharges
0 USD
dva Debt Refinancing Charges
DebtRefinancingCharges
884000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
51717000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
42125000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
40685000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
132101000 USD
us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
2764000 USD
us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
6494000 USD
dva Gain Loss On Disposition Of Business Interests Before Tax
GainLossOnDispositionOfBusinessInterestsBeforeTax
0 USD
dva Gain Loss On Disposition Of Business Interests Before Tax
GainLossOnDispositionOfBusinessInterestsBeforeTax
-16252000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1274000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
5885000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
117171000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15194000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3270000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
696000 USD
dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
-14465000 USD
dva Increase Decrease In Other Current Receivables And Other Current Assets
IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets
131988000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
13706000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1950000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-47390000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-15858000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-90381000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-19325000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
25090000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
146490000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
10753000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-4800000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-13232000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-13269000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
834036000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1011503000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
294438000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
291667000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
23890000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
44267000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
29774000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
70615000 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
7923000 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
142483000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
2164000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
3034000 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
7923000 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
7621000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
11908000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
3438000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
6029000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
8101000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
1140000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
739000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-283699000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-407139000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1611086000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2324300000 USD
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
754407000 USD
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
635695000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
9089000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
20375000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
560507000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
321798000 USD
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
99362000 USD
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
118553000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
43605000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2106000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
15925000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
20582000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
4493000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
6782000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
155548000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1239573000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1197000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-16936000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
704688000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1827001000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
501790000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1208718000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1206478000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3035719000 USD
CY2021Q2 us-gaap Revenues
Revenues
2916510000 USD
CY2020Q2 us-gaap Revenues
Revenues
2879979000 USD
us-gaap Revenues
Revenues
5736511000 USD
us-gaap Revenues
Revenues
5721216000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
293820000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
201602000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
531223000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
431215000 USD
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2020Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
9980000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
293820000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
201602000 USD
us-gaap Net Income Loss
NetIncomeLoss
531223000 USD
us-gaap Net Income Loss
NetIncomeLoss
441195000 USD
CY2021Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
106364000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
122074000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
107606000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
123485000 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
5059000 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1994000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
4949000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1994000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111423000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
124068000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112555000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125479000 shares
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.76
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.65
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
4.94
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
3.49
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2020Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.08
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.76
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.57
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.64
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.62
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
4.72
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
3.44
CY2021Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0
CY2020Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0.08
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.64
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.52
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
141000 shares
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3216000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
84000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3211000 shares
CY2021Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
8222000 USD
CY2021Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
62256000 USD
CY2021Q2 us-gaap Marketable Securities
MarketableSecurities
70478000 USD
CY2020Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
8217000 USD
CY2020Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
44077000 USD
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
52294000 USD
CY2021Q2 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8222000 USD
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
36701000 USD
CY2020Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8217000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20101000 USD
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
32193000 USD
CY2021Q2 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
0 USD
CY2021Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
33777000 USD
CY2021Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
8222000 USD
CY2021Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
62256000 USD
CY2021Q2 us-gaap Marketable Securities
MarketableSecurities
70478000 USD
CY2020Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
8217000 USD
CY2020Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
44077000 USD
CY2020Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
0 USD
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
52294000 USD
CY2021Q2 us-gaap Equity Securities Fv Ni Unrealized Gain
EquitySecuritiesFvNiUnrealizedGain
8328000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
6787635000 USD
CY2020 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
130057000 USD
CY2020 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
8293000 USD
CY2020 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-9710000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
6919109000 USD
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
28323000 USD
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
3767000 USD
CY2021Q2 us-gaap Goodwill
Goodwill
6943665000 USD
CY2021Q2 us-gaap Goodwill Gross
GoodwillGross
7075816000 USD
CY2021Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
132151000 USD
CY2021Q2 us-gaap Goodwill
Goodwill
6943665000 USD
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.188
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.246
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.206
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.247
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
9045563000 USD
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8163521000 USD
CY2021Q2 dva Discount And Deferred Finance Costs
DiscountAndDeferredFinanceCosts
62865000 USD
CY2020Q4 dva Discount And Deferred Finance Costs
DiscountAndDeferredFinanceCosts
77717000 USD
CY2021Q2 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
8982698000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
8085804000 USD
CY2021Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
184435000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
168541000 USD
CY2021Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
8798263000 USD
CY2020Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
7917263000 USD
CY2021Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0336
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0322
CY2021Q2 us-gaap Longterm Debt Weighted Average Interest Rate
LongtermDebtWeightedAverageInterestRate
0.0333
CY2021Q2 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.51
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">contingencies</span>The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, governmental investigations (which frequently arise from qui tam suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of June 30, 2021 and December 31, 2020, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Governmental Inquiries and Related Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2016 U.S. Attorney Texas Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In February 2016, DaVita Rx, LLC (DaVita Rx), a wholly-owned subsidiary of the Company, received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office, Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company’s relationships with pharmaceutical manufacturers. The government’s investigation covers the period from January 1, 2006 through December 31, 2018. In December 2017, the Company finalized and executed a settlement agreement that resolved certain of the issues in the government’s investigation and that included total monetary consideration of $63,700, as previously disclosed, of which $41,500 was an incremental cash payment and $22,200 was for amounts previously refunded, and all of which was previously accrued. The government’s investigation is ongoing with respect to issues related to DaVita Rx’s historic relationships with certain pharmaceutical manufacturers, and in July 2018 the Office of Inspector General (OIG) served the Company with a subpoena seeking additional documents and information relating to those relationships. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2017 U.S. Attorney Colorado Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In November 2017, the U.S. Attorney’s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company’s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is continuing to cooperate with the government in this investigation. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2018 U.S. Attorney Florida Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2018, DaVita Labs received two CIDs from the U.S. Attorney’s Office, Middle District of Florida that were identical in nature but directed to the two different labs. According to the face of the CIDs, the U.S. Attorney’s Office is conducting an investigation as to whether the Company’s subsidiary submitted claims for blood, urine, and fecal testing, where there were insufficient test validation or stability studies to ensure accurate results, in violation of the FCA. In October 2018, DaVita Labs received a subpoena from the OIG in connection with this matter requesting certain patient records linked to clinical laboratory tests. On September 30, 2019, the U.S. Attorney’s Office notified the U.S. District Court, Middle District of Florida, of its decision not to elect to intervene at this time in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. ex rel. Lorne Holland, et al. v. DaVita Healthcare Partners, Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The court then unsealed the complaint, which alleges </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">violations of the FCA, by order dated the same day. In January 2020, the private party relators served the Company and DaVita Labs with an amended complaint. On February 24, 2020, the Company and DaVita Labs filed a motion to dismiss the amended complaint. On June 25, 2020, the court denied the motion to dismiss. The Company and DaVita Labs answered the complaint on July 23, 2020. The Company and DaVita Labs dispute these allegations and intend to defend this action accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 U.S. Attorney New Jersey Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In March 2020, the U.S. Attorney’s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney’s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company’s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired October 22, 2019. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 California Department of Insurance Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020. The subpoena, as revised, requests information on a number of topics, including but not limited to the Company’s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients’ decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is cooperating with CDI in this investigation.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2020 Department of Justice Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In October 2020, the Company received a CID from the Department of Justice pursuant to a False Claims Act investigation concerning allegations that DaVita Medical Group (DMG) may have submitted undocumented or unsupported diagnosis codes in connection with Medicare Advantage beneficiaries. The CID covers the period from January 1, 2015 through June 19, 2019, the date the Company completed the divestiture of DMG to Collaborative Care Holdings, LLC. The Company is cooperating with the government in this investigation.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to qui tam complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Proceedings</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Antitrust Indictment and Putative Class Action Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The two count indictment alleges that purported agreements entered into by its former chief executive officer not to solicit senior-level employees violate Section 1 of the Sherman Act. On July 16, 2021, a former DaVita employee filed a putative class action complaint in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pena v. Surgical Care Affiliates, LLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. District Court, Northern District of Illinois based on the allegations in the matter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. v. DaVita Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The complaint seeks to bring an action on behalf of the defendant and similarly situated individuals, including without limitation those employed by the Company between February 1, 2012 through June 30, 2019 as senior-level employees. The Company disputes the allegations in the indictment and the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend these actions accordingly.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 8, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.</span></div><div style="margin-top:9pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resolved Matters</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Peace Officers’ Annuity and Benefit Fund of Georgia Securities Class Action Civil Suit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On February 1, 2017, the Peace Officers’ Annuity and Benefit Fund of Georgia filed a putative federal securities class action complaint in the U.S. District Court for the District of Colorado against the Company and certain executives. The complaint covers the time period of August 2015 to October 2016 and alleges, generally, that the Company and its executives violated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal securities laws concerning the Company’s financial results and revenue derived from patients who received charitable premium assistance from an industry-funded non-profit organization. The complaint further alleges that the process by which patients obtained commercial insurance and received charitable premium assistance was improper and "created a false impression of DaVita’s business and operational status and future growth prospects."</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company continues to dispute the allegations, it reached an agreement to resolve this matter without admitting to any liability. Settlement of this matter was covered primarily with insurance proceeds. The Company contributed an amount that did not have a material impact on the Company’s consolidated financial position, results of operations or cash flows. On April 13, 2021, the court granted final approval of the settlement. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">In re DaVita Inc. Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On August 15, 2017, the U.S. District Court for the District of Delaware consolidated three previously disclosed shareholder derivative lawsuits: the Blackburn Shareholder action filed on February 10, 2017, the Gabilondo Shareholder action filed on May 30, 2017, and the City of Warren Police and Fire Retirement System Shareholder action filed on June 9, 2017. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the defendants continue to dispute the allegations, an agreement was reached to resolve this matter without admitting to any liability and the court approved the settlement on January 29, 2021. As part of the settlement, the Company agreed to certain corporate governance policies, but did not make any financial contribution towards the settlement.</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* * *</span></div>
dva Corporate Integrity Agreement Expiration Date
CorporateIntegrityAgreementExpirationDate
2019-10-22
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
204649000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2020Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
2000000000 USD
CY2021Q2 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
27159000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
9980000 USD
CY2021Q2 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
25495000 USD
CY2021Q2 dva Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average Ebitda Multiple
PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple
180000000 USD
CY2021Q2 us-gaap Revenues
Revenues
2916510000 USD
CY2020Q2 us-gaap Revenues
Revenues
2879979000 USD
us-gaap Revenues
Revenues
5736511000 USD
us-gaap Revenues
Revenues
5721216000 USD
CY2020Q2 dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
73088000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
933078000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
875296000 USD
CY2021Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
73324000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
169984000 USD
dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
50940000 USD
dva Segment Reporting Information Corporate Expenses
SegmentReportingInformationCorporateExpenses
96672000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
490476000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
409920000 USD
CY2020Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
81381000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
140338000 USD
CY2021Q2 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
CY2020Q2 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
0 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
2948000 USD
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15188000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9545000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
338084000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
809096000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16356000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5195000 USD
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
432340000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
707559000 USD
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
169689000 USD
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
157376000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
335390000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
312055000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
294438000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
291667000 USD
CY2021Q2 us-gaap Assets
Assets
17810311000 USD
CY2020Q4 us-gaap Assets
Assets
16988516000 USD

Files In Submission

Name View Source Status
0000927066-21-000136-index-headers.html Edgar Link pending
0000927066-21-000136-index.html Edgar Link pending
0000927066-21-000136.txt Edgar Link pending
0000927066-21-000136-xbrl.zip Edgar Link pending
dva-20210630.htm Edgar Link pending
dva-20210630.xsd Edgar Link pending
dva-20210630_cal.xml Edgar Link unprocessable
dva-20210630_def.xml Edgar Link unprocessable
dva-20210630_g1.jpg Edgar Link pending
dva-20210630_htm.xml Edgar Link completed
dva-20210630_lab.xml Edgar Link unprocessable
dva-20210630_pre.xml Edgar Link unprocessable
dva-63021ex31110xq.htm Edgar Link pending
dva-63021ex31210xq.htm Edgar Link pending
dva-63021ex32110xq.htm Edgar Link pending
dva-63021ex32210xq.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending